Skip to content

Editorial Policy

Last updated: November 2026

Who we are

BiohackingHub is written and edited by a small, independent editorial team led by the site’s founder, who publishes under the pen name Elias Varden and is not a clinician. There are no physicians or licensed clinicians on staff, and no page on this site is reviewed by a clinician. Nothing here is medical advice: when we say a dose or a protocol is “supported”, we mean that the cited trials support it, not that it is a recommendation for you. Decisions about prescription compounds belong with your doctor.

How content is produced

  1. Literature search. We search PubMed for randomised trials, meta-analyses, cohort studies and mechanistic work on the compound or question. Search and first-pass summarisation are AI-assisted.
  2. Drafting and editing. The team writes and edits the page against the papers, not against the summaries. Claims that cannot be tied to a specific study are cut.
  3. Source verification. Every PubMed ID in the reference list is resolved through NCBI E-utilities before publication. A reference that does not exist, or whose abstract does not support the sentence it is attached to, is removed and the sentence is rewritten or deleted.
  4. Evidence grading. Each page is graded on the Oxford CEBM scale. The overall grade is set by the weakest claim the page depends on, not by the strongest study it cites.
  5. Compliance check. Substance profiles carry FDA (US) and EC 1924/2006 (EU) compliant wording. Prescription-only compounds and research-only peptides are labelled as such.
  6. Publication and updates. Pages show their publication date and the date of the last editorial review. Profiles are re-read when significant new evidence appears.

Evidence grading

All content is graded using the Oxford Centre for Evidence-Based Medicine (CEBM) scale:

  • Level 1a/1b: Systematic reviews and randomised controlled trials
  • Level 2a/2b: Cohort studies and lower-quality RCTs
  • Level 3: Case-control studies
  • Level 4: Case series and poor-quality cohort studies
  • Level 5: Expert opinion, mechanistic reasoning

Each substance also receives an overall Evidence Grade (A = multiple human RCTs or meta-analysis; D = anecdotal or in-vitro only) and a Safety Tier (A = well-established safety; D = significant risk).

Use of AI

We use AI tools for literature search, first-pass summarisation and copy-editing. We do not publish AI output unedited, and no reference reaches a page without being resolved against PubMed by the process above. Where a page was produced with AI assistance, this policy is the disclosure.

Independence

The team is not compensated by supplement brands, peptide vendors or pharmaceutical companies. Sponsored content and paid links are labelled and carry rel="sponsored"; they never appear inside substance profiles or protocols and do not influence Evidence Grades, Safety Tiers or safety warnings. See the affiliate disclosure.

Corrections

Factual errors are corrected promptly, and the page notes what changed and when. If you find an inaccuracy, write to promo@westernhealthscreening.com with the page URL and the source that contradicts it.

Update policy

Substance profiles are reviewed when significant new evidence is published. The “Last reviewed” date on each profile reflects the most recent editorial read-through. We aim to re-read every profile at least once a year.